Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Regencell Bioscience Holdings Ltd RGC

Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.


NDAQ:RGC - Post by User

User Avatar Image
(0)
•••
  • sungrin1309X
Post by sungrin1309on Oct 22, 2022 9:13am
114 Views
Post# 35040782

RGC share buyback by Company CEO/Philanthropist

RGC share buyback by Company CEO/PhilanthropistRGC a healthcare company which has been on the target of shortsellers in Q2 22’ is taking on the full might of the company CEO.

Based on the the CEO’s Schedule 13D fillings with the SEC (US Security and Exchange Commission), CEO (Mr Au) has used an aggregate of $5.03 mil of his personal funds to purchase ordinary shares on open market between July 2021 and May 2022. A total of 10,539,159 ordinary shares are now owned by the Mr Au, which represents approximately 81% of company’s total issued and outstanding ordinary shares.

The company’s mission is to develop a natural treatment method for neurocognitive disorders and degenerations, specifically ADHD and ASD, and infectious diseases affecting people’s immune system such as COVID-19.

Aside from RGC’s approach in developing successful treatments for ADHD and ASD, Mr Au is also been involved in his own philanthropic project (within his own means) and aims to provided care to over 10,000 affected children with ADHD, ASD and Covid-19 and also those affected by financial difficulties. As of today, Mr Au’s project has personally helped over 150 children since the launch of this project on April 16, 22.
<< Previous
Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities